Doximity price target raised to $32 from $29 at BofA

BofA raised the firm’s price target on Doximity to $32 from $29 and keeps a Neutral rating on the shares. The firm, which notes its price target increase is primarily due to peer multiple expansion, conducted its seventh quarterly survey on pharmaceutical advertising and found that macro headwinds and budget pressures appear to be stabilizing, but added that the competitive landscape “appears to be evolving again.”